Clear All
11110 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
64842-1020-03 64842-1020 Trifluridine and Tipiracil Lonsurf 8.19 mg/1, 20.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct 21, 2015 In Use
73462-0101-01 73462-0101 Trilaciclib Cosela 300.0 mg/20mL Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Intravenous Feb 12, 2021 In Use
52544-0092-76 52544-0092 Triptorelin Pamoate Trelstar Hormonal Therapy GnRH Agonist Mar 11, 2010 Oct 31, 2018 No Longer Used
00023-5902-04 00023-5902 Triptorelin Pamoate Trelstar Hormonal Therapy GnRH Agonist Jun 15, 2000 In Use
52544-0189-76 52544-0189 Triptorelin Pamoate Trelstar Hormonal Therapy GnRH Agonist Jun 15, 2000 Oct 31, 2018 No Longer Used
52544-0154-02 52544-0154 Triptorelin Pamoate Trelstar 11.25 mg/2mL Hormonal Therapy GnRH Agonist Intramuscular Jun 29, 2001 Oct 31, 2018 No Longer Used
00023-5904-12 00023-5904 Triptorelin Pamoate Trelstar Hormonal Therapy GnRH Agonist Jun 29, 2001 In Use
52544-0188-76 52544-0188 Triptorelin Pamoate Trelstar Hormonal Therapy GnRH Agonist Jun 29, 2001 Oct 31, 2018 No Longer Used
52544-0153-02 52544-0153 Triptorelin Pamoate Trelstar 3.75 mg/2mL Hormonal Therapy GnRH Agonist Intramuscular Jun 15, 2000 Oct 31, 2018 No Longer Used
52544-0156-02 52544-0156 Triptorelin Pamoate Trelstar 22.5 mg/2mL Hormonal Therapy GnRH Agonist Intramuscular Mar 11, 2010 Oct 31, 2018 No Longer Used
00023-5906-23 00023-5906 Triptorelin Pamoate Trelstar Hormonal Therapy GnRH Agonist Mar 11, 2010 In Use
51144-0002-60 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral Apr 17, 2020 In Use
51144-0002-12 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral Apr 17, 2020 In Use
51144-0001-60 51144-0001 Tucatinib TUKYSA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral Apr 17, 2020 In Use
73150-0200-12 73150-0200 umbralisib UKONIQ 260.2 mg/1 Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Oral Feb 5, 2021 Jul 31, 2023 No Longer Used
69468-0151-04 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Mar 1, 2016 In Use
50633-0220-20 50633-0220 Uridine triacetate VISTOGARD 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Jul 31, 2024 In Use
69468-0151-10 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Mar 1, 2016 In Use
69468-0151-20 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Mar 1, 2016 In Use
50633-0220-04 50633-0220 Uridine triacetate VISTOGARD 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral Jul 31, 2024 In Use
24201-0101-04 24201-0101 Valrubicin Intravesical Solution Valrubicin Intravesical Solution 40.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravesical Apr 23, 2019 In Use
67979-0001-02 67979-0001 Valrubicin Valstar 40.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravesical Oct 1, 1998 Oct 17, 2017 In Use
67979-0001-01 67979-0001 Valrubicin Valstar 40.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravesical Oct 1, 1998 In Use
00310-7810-30 00310-7810 Vandetanib Vandetanib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Oral Apr 21, 2011 Jun 22, 2013 No Longer Used
58468-7820-03 58468-7820 Vandetanib Caprelsa 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Oral Jul 25, 2011 In Use

Found 11110 results — Export these results